 id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cole</surname><given-names>ST</given-names></name><name><surname>Riccardi</surname><given-names>G</given-names></name></person-group><article-title>New tuberculosis drugs on the horizon</article-title><source>Curr Opin Microbiol</source><year>2011</year><volume>14</volume><issue>5</issue><fpage>570</fpage><lpage>576</lpage><pub-id pub-id-type="doi">10.1016/j.mib.2011.07.022</pub-id><pub-id pub-id-type="pmid">21821466</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harrington</surname><given-names>M</given-names></name></person-group><article-title>From HIV to tuberculosis and back again: a tale of activism in 2 pandemics</article-title><source>Clin Infect Dis</source><year>2010</year><volume>50</volume><issue>Supplement_3</issue><fpage>S260</fpage><lpage>S266</lpage><pub-id pub-id-type="doi">10.1086/651500</pub-id><pub-id pub-id-type="pmid">20397957</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Medapi</surname><given-names>B</given-names></name><name><surname>Renuka</surname><given-names>J</given-names></name><name><surname>Saxena</surname><given-names>S</given-names></name><etal/></person-group><article-title>Design and synthesis of novel quinoline&#x02013;aminopiperidine hybrid analogues as <italic>Mycobacterium tuberculosis</italic> DNA gyraseB inhibitors</article-title><source>Bioorg Med Chem</source><year>2015</year><volume>23</volume><issue>9</issue><fpage>2062</fpage><lpage>2078</lpage><pub-id pub-id-type="doi">10.1016/j.bmc.2015.03.004</pub-id><pub-id pub-id-type="pmid">25801151</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aagaard</surname><given-names>C</given-names></name><name><surname>Hoang</surname><given-names>T</given-names></name><name><surname>Dietrich</surname><given-names>J</given-names></name><etal/></person-group><article-title>A multistage tuberculosis vaccine that confers efficient protection before and after exposure</article-title><source>Nat Med</source><year>2011</year><volume>17</volume><issue>2</issue><fpage>189</fpage><lpage>194</lpage><pub-id pub-id-type="doi">10.1038/nm.2285</pub-id><pub-id pub-id-type="pmid">21258338</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chao</surname><given-names>MC</given-names></name><name><surname>Rubin</surname><given-names>EJ</given-names></name></person-group><article-title>Letting sleeping dos lie: does dormancy play a role in tuberculosis?</article-title><source>Annu Rev Microbiol</source><year>2010</year><volume>64</volume><fpage>293</fpage><lpage>311</lpage><pub-id pub-id-type="doi">10.1146/annurev.micro.112408.134043</pub-id><pub-id pub-id-type="pmid">20825351</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>Z</given-names></name><name><surname>Lienhardt</surname><given-names>C</given-names></name><name><surname>McIlleron</surname><given-names>H</given-names></name><etal/></person-group><article-title>Global tuberculosis drug development pipeline: the need and the reality</article-title><source>Lancet</source><year>2010</year><volume>375</volume><issue>9731</issue><fpage>2100</fpage><lpage>2109</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(10)60359-9</pub-id><pub-id pub-id-type="pmid">20488518</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koul</surname><given-names>A</given-names></name><name><surname>Arnoult</surname><given-names>E</given-names></name><name><surname>Lounis</surname><given-names>N</given-names></name><etal/></person-group><article-title>The challenge of new drug discovery for tuberculosis</article-title><source>Nature</source><year>2011</year><volume>469</volume><issue>7331</issue><fpage>483</fpage><lpage>490</lpage><pub-id pub-id-type="doi">10.1038/nature09657</pub-id><pub-id pub-id-type="pmid">21270886</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ginsberg</surname><given-names>AM</given-names></name></person-group><article-title>Drugs in development for tuberculosis</article-title><source>Drugs</source><year>2010</year><volume>70</volume><issue>17</issue><fpage>2201</fpage><lpage>2214</lpage><pub-id pub-id-type="doi">10.2165/11538170-000000000-00000</pub-id><pub-id pub-id-type="pmid">21080738</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lindenberger</surname><given-names>JJ</given-names></name><name><surname>Veleti</surname><given-names>SK</given-names></name><name><surname>Wilson</surname><given-names>BN</given-names></name><etal/></person-group><article-title>Crystal structures of <italic>Mycobacterium tuberculosis</italic> GlgE and complexes with non-covalent inhibitors</article-title><source>Sci Rep</source><year>2015</year><volume>5</volume><fpage>12830</fpage><pub-id pub-id-type="doi">10.1038/srep12830</pub-id><pub-id pub-id-type="pmid">26245983</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manina</surname><given-names>G</given-names></name><name><surname>Pasca</surname><given-names>MR</given-names></name><name><surname>Buroni</surname><given-names>S</given-names></name><etal/></person-group><article-title>Decaprenylphosphoryl-&#x003b2;-<sc>d</sc>-ribose 2&#x02032;-epimerase from <italic>Mycobacterium tuberculosis</italic> is a magic drug target</article-title><source>Curr Med Chem</source><year>2010</year><volume>17</volume><issue>27</issue><fpage>3099</fpage><lpage>3108</lpage><pub-id pub-id-type="doi">10.2174/092986710791959693</pub-id><pub-id pub-id-type="pmid">20629622</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parchina</surname><given-names>A</given-names></name><name><surname>Froeyen</surname><given-names>M</given-names></name><name><surname>Margamuljana</surname><given-names>L</given-names></name><etal/></person-group><article-title>Discovery of an acyclic nucleoside phosphonate that inhibits <italic>Mycobacterium tuberculosis</italic> ThyX based on the binding mode of a 5-alkynyl substrate analogue</article-title><source>ChemMedChem</source><year>2013</year><volume>8</volume><issue>8</issue><fpage>1373</fpage><lpage>1383</lpage><pub-id pub-id-type="doi">10.1002/cmdc.201300146</pub-id><pub-id pub-id-type="pmid">23836539</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trefzer</surname><given-names>C</given-names></name><name><surname>&#x00160;kovierov&#x000e1;</surname><given-names>H</given-names></name><name><surname>Buroni</surname><given-names>S</given-names></name><etal/></person-group><article-title>Benzothiazinones are suicide inhibitors of mycobacterial decaprenylphosphoryl-&#x003b2;-<sc>d</sc>-ribofuranose 2&#x02032;-oxidase DprE1</article-title><source>J Am Chem Soc</source><year>2011</year><volume>134</volume><issue>2</issue><fpage>912</fpage><lpage>915</lpage><pub-id pub-id-type="doi">10.1021/ja211042r</pub-id><pub-id pub-id-type="pmid">22188377</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meniche</surname><given-names>X</given-names></name><name><surname>De Sousa-D&#x02019;Auria</surname><given-names>C</given-names></name><name><surname>Van-der-Rest</surname><given-names>B</given-names></name><etal/></person-group><article-title>Partial redundancy in the synthesis of the <sc>d</sc>-arabinose incorporated in the cell wall arabinan of Corynebacterineae</article-title><source>Microbiology</source><year>2008</year><volume>154</volume><issue>8</issue><fpage>2315</fpage><lpage>2326</lpage><pub-id pub-id-type="doi">10.1099/mic.0.2008/016378-0</pub-id><pub-id pub-id-type="pmid">18667564</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Batt</surname><given-names>SM</given-names></name><name><surname>Jabeen</surname><given-names>T</given-names></name><name><surname>Bhowruth</surname><given-names>V</given-names></name><etal/></person-group><article-title>Structural basis of inhibition of <italic>Mycobacterium tuberculosis</italic> DprE1 by benzothiazinone inhibitors</article-title><source>Proc Natl Acad Sci</source><year>2012</year><volume>109</volume><issue>28</issue><fpage>11354</fpage><lpage>11359</lpage><pub-id pub-id-type="doi">10.1073/pnas.1205735109</pub-id><pub-id pub-id-type="pmid">22733761</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luciani</surname><given-names>R</given-names></name><name><surname>Saxena</surname><given-names>P</given-names></name><name><surname>Surade</surname><given-names>S</given-names></name><etal/></person-group><article-title>Virtual screening and X-ray crystallography identify non-substrate analog inhibitors of flavin-dependent thymidylate synthase</article-title><source>J Med Chem</source><year>2016</year><volume>59</volume><issue>19</issue><fpage>9269</fpage><lpage>9275</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.6b00977</pub-id><pub-id pub-id-type="pmid">27589670</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Landge</surname><given-names>S</given-names></name><name><surname>Mullick</surname><given-names>AB</given-names></name><name><surname>Nagalapur</surname><given-names>K</given-names></name><etal/></person-group><article-title>Discovery of benzothiazoles as antimycobacterial agents: synthesis, structure&#x02013;activity relationships and binding studies with <italic>Mycobacterium tuberculosis</italic> decaprenylphosphoryl-&#x003b2;-<sc>d</sc>-ribose 2&#x02032;-oxidase</article-title><source>Bioorg Med Chem</source><year>2015</year><volume>23</volume><issue>24</issue><fpage>7694</fpage><lpage>7710</lpage><pub-id pub-id-type="doi">10.1016/j.bmc.2015.11.017</pub-id><pub-id pub-id-type="pmid">26643218</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Makarov</surname><given-names>V</given-names></name><name><surname>Lechartier</surname><given-names>B</given-names></name><name><surname>Zhang</surname><given-names>M</given-names></name><etal/></person-group><article-title>Towards a new combination therapy for tuberculosis with next generation benzothiazinones</article-title><source>EMBO Mol Med</source><year>2014</year></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Piton</surname><given-names>J</given-names></name><name><surname>Foo</surname><given-names>CSY</given-names></name><name><surname>Cole</surname><given-names>ST</given-names></name></person-group><article-title>Structural studies of <italic>Mycobacterium tuberculosis</italic> DprE1 interacting with its inhibitors</article-title><source>Drug Discov Today</source><year>2017</year><volume>22</volume><issue>3</issue><fpage>526</fpage><lpage>533</lpage><pub-id pub-id-type="doi">10.1016/j.drudis.2016.09.014</pub-id><pub-id pub-id-type="pmid">27666194</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jeankumar</surname><given-names>VU</given-names></name><name><surname>Renuka</surname><given-names>J</given-names></name><name><surname>Pulla</surname><given-names>VK</given-names></name><etal/></person-group><article-title>Development of novel N-linked aminopiperidine-based mycobacterial DNA gyrase B inhibitors: scaffold hopping from known antibacterial leads</article-title><source>Int J Antimicrob Agents</source><year>2014</year><volume>43</volume><issue>3</issue><fpage>269</fpage><lpage>278</lpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2013.12.006</pub-id><pub-id pub-id-type="pmid">24434114</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Riccardi</surname><given-names>G</given-names></name><name><surname>Pasca</surname><given-names>MR</given-names></name><name><surname>Chiarelli</surname><given-names>LR</given-names></name><etal/></person-group><article-title>The DprE1 enzyme, one of the most vulnerable targets of <italic>Mycobacterium tuberculosis</italic></article-title><source>Appl Microbiol Biotechnol</source><year>2013</year><volume>97</volume><issue>20</issue><fpage>8841</fpage><lpage>8848</lpage><pub-id pub-id-type="doi">10.1007/s00253-013-5218-x</pub-id><pub-id pub-id-type="pmid">24037308</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crellin</surname><given-names>PK</given-names></name><name><surname>Brammananth</surname><given-names>R</given-names></name><name><surname>Coppel</surname><given-names>RL</given-names></name></person-group><article-title>Decaprenylphosphoryl-&#x003b2;-<sc>d</sc>-ribose 2&#x02032;-epimerase, the target of benzothiazinones and dinitrobenzamides, is an essential enzyme in <italic>Mycobacterium smegmatis</italic></article-title><source>PLoS ONE</source><year>2011</year><volume>6</volume><issue>2</issue><fpage>e16869</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0016869</pub-id><pub-id pub-id-type="pmid">21346818</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kolly</surname><given-names>GS</given-names></name><name><surname>Boldrin</surname><given-names>F</given-names></name><name><surname>Sala</surname><given-names>C</given-names></name><etal/></person-group><article-title>Assessing the essentiality of the decaprenyl-phospho-<sc>d</sc>-arabinofuranose pathway in <italic>Mycobacterium tuberculosis</italic> using conditional mutants</article-title><source>Mol Microbiol</source><year>2014</year><volume>92</volume><issue>1</issue><fpage>194</fpage><lpage>211</lpage><pub-id pub-id-type="doi">10.1111/mmi.12546</pub-id><pub-id pub-id-type="pmid">24517327</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Makarov</surname><given-names>V</given-names></name><name><surname>Manina</surname><given-names>G</given-names></name><name><surname>Mikusova</surname><given-names>K</given-names></name><etal/></person-group><article-title>Benzothiazinones kill <italic>Mycobacterium tuberculosis</italic> by blocking arabinan synthesis</article-title><source>Science</source><year>2009</year><volume>324</volume><issue>5928</issue><fpage>801</fpage><lpage>804</lpage><pub-id pub-id-type="doi">10.1126/science.1171583</pub-id><pub-id pub-id-type="pmid">19299584</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brecik</surname><given-names>M</given-names></name><name><surname>Cent&#x000e1;rov&#x000e1;</surname><given-names>I</given-names></name><name><surname>Mukherjee</surname><given-names>R</given-names></name><etal/></person-group><article-title>DprE1 is a vulnerable tuberculosis drug target due to its cell wall localization</article-title><source>ACS Chem Biol</source><year>2015</year><volume>10</volume><issue>7</issue><fpage>1631</fpage><lpage>1636</lpage><pub-id pub-id-type="doi">10.1021/acschembio.5b00237</pub-id><pub-id pub-id-type="pmid">25906160</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Narender</surname><given-names>M</given-names></name><name><surname>Umasankar</surname><given-names>K</given-names></name><name><surname>Malathi</surname><given-names>J</given-names></name><etal/></person-group><article-title>Synthesis, in vitro antimycobacterial evaluation and docking studies of some new 5,6,7,8-tetrahydropyrido[4&#x02032;,3&#x02032;:4,5]thieno[2,3-d] pyrimidin-4(3<italic>H</italic>)-one schiff bases</article-title><source>Bioorg Med Chem Lett</source><year>2016</year><volume>26</volume><issue>3</issue><fpage>836</fpage><lpage>840</lpage><pub-id pub-id-type="doi">10.1016/j.bmcl.2015.12.083</pub-id><pub-id pub-id-type="pmid">26755393</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stanley</surname><given-names>SA</given-names></name><name><surname>Grant</surname><given-names>SS</given-names></name><name><surname>Kawate</surname><given-names>T</given-names></name><etal/></person-group><article-title>Identification of novel inhibitors of <italic>M. tuberculosis</italic> growth using whole cell based high-throughput screening</article-title><source>ACS Chem Biol</source><year>2012</year><volume>7</volume><issue>8</issue><fpage>1377</fpage><lpage>1384</lpage><pub-id pub-id-type="doi">10.1021/cb300151m</pub-id><pub-id pub-id-type="pmid">22577943</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>F</given-names></name><name><surname>Sambandan</surname><given-names>D</given-names></name><name><surname>Halder</surname><given-names>R</given-names></name><etal/></person-group><article-title>Identification of a small molecule with activity against drug-resistant and persistent tuberculosis</article-title><source>Proc Natl Acad Sci</source><year>2013</year><volume>110</volume><issue>27</issue><fpage>E2510</fpage><lpage>E2517</lpage><pub-id pub-id-type="doi">10.1073/pnas.1309171110</pub-id><pub-id pub-id-type="pmid">23776209</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kieser</surname><given-names>KJ</given-names></name><name><surname>Rubin</surname><given-names>EJ</given-names></name></person-group><article-title>How sisters grow apart: mycobacterial growth and division</article-title><source>Nat Rev Microbiol</source><year>2014</year><volume>12</volume><issue>8</issue><fpage>550</fpage><lpage>562</lpage><pub-id pub-id-type="doi">10.1038/nrmicro3299</pub-id><pub-id pub-id-type="pmid">24998739</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takayama</surname><given-names>K</given-names></name><name><surname>Kilburn</surname><given-names>JO</given-names></name></person-group><article-title>Inhibition of synthesis of arabinogalactan by ethambutol in <italic>Mycobacterium smegmatis</italic></article-title><source>Antimicrob Agents Chemother</source><year>1989</year><volume>33</volume><issue>9</issue><fpage>1493</fpage><lpage>1499</lpage><pub-id pub-id-type="doi">10.1128/AAC.33.9.1493</pub-id><pub-id pub-id-type="pmid">2817850</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chikhale</surname><given-names>R</given-names></name><name><surname>Menghani</surname><given-names>S</given-names></name><name><surname>Babu</surname><given-names>R</given-names></name><etal/></person-group><article-title>Development of selective DprE1 inhibitors: design, synthesis, crystal structure and antitubercular activity of benzothiazolylpyrimidine-5-carboxamides</article-title><source>Eur J Med Chem</source><year>2015</year><volume>96</volume><fpage>30</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1016/j.ejmech.2015.04.011</pub-id><pub-id pub-id-type="pmid">25874329</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Villemagne</surname><given-names>B</given-names></name><name><surname>Crauste</surname><given-names>C</given-names></name><name><surname>Flipo</surname><given-names>M</given-names></name><etal/></person-group><article-title>Tuberculosis: the drug development pipeline at a glance</article-title><source>Eur J Med Chem</source><year>2012</year><volume>51</volume><fpage>1</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1016/j.ejmech.2012.02.033</pub-id><pub-id pub-id-type="pmid">22421275</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chatterji</surname><given-names>M</given-names></name><name><surname>Shandil</surname><given-names>R</given-names></name><name><surname>Manjunatha</surname><given-names>M</given-names></name><etal/></person-group><article-title>1,4-Azaindole, a potential drug candidate for treatment of tuberculosis</article-title><source>Antimicrob Agents Chemother</source><year>2014</year><volume>58</volume><issue>9</issue><fpage>5325</fpage><lpage>5331</lpage><pub-id pub-id-type="doi">10.1128/AAC.03233-14</pub-id><pub-id pub-id-type="pmid">24957839</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Panda</surname><given-names>M</given-names></name><name><surname>Ramachandran</surname><given-names>S</given-names></name><name><surname>Ramachandran</surname><given-names>V</given-names></name><etal/></person-group><article-title>Discovery of pyrazolopyridones as a novel class of noncovalent DprE1 inhibitor with potent anti-mycobacterial activity</article-title><source>J Med Chem</source><year>2014</year><volume>57</volume><issue>11</issue><fpage>4761</fpage><lpage>4771</lpage><pub-id pub-id-type="doi">10.1021/jm5002937</pub-id><pub-id pub-id-type="pmid">24818517</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shirude</surname><given-names>PS</given-names></name><name><surname>Shandil</surname><given-names>R</given-names></name><name><surname>Sadler</surname><given-names>C</given-names></name><etal/></person-group><article-title>Azaindoles: noncovalent DprE1 inhibitors from scaffold morphing efforts, kill <italic>Mycobacterium tuberculosis</italic> and are efficacious in vivo</article-title><source>J Med Chem</source><year>2013</year><volume>56</volume><issue>23</issue><fpage>9701</fpage><lpage>9708</lpage><pub-id pub-id-type="doi">10.1021/jm401382v</pub-id><pub-id pub-id-type="pmid">24215368</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Christophe</surname><given-names>T</given-names></name><name><surname>Jackson</surname><given-names>M</given-names></name><name><surname>Jeon</surname><given-names>HK</given-names></name><etal/></person-group><article-title>High content screening identifies decaprenyl-phosphoribose 2&#x02032; epimerase as a target for intracellular antimycobacterial inhibitors</article-title><source>PLoS Pathog</source><year>2009</year><volume>5</volume><issue>10</issue><fpage>e1000645</fpage><pub-id pub-id-type="doi">10.1371/journal.ppat.1000645</pub-id><pub-id pub-id-type="pmid">19876393</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Naik</surname><given-names>M</given-names></name><name><surname>Humnabadkar</surname><given-names>V</given-names></name><name><surname>Tantry</surname><given-names>SJ</given-names></name><etal/></person-group><article-title>4-Aminoquinolone piperidine amides: noncovalent inhibitors of DprE1 with long residence time and potent antimycobacterial activity</article-title><source>J Med Chem</source><year>2014</year><volume>57</volume><issue>12</issue><fpage>5419</fpage><lpage>5434</lpage><pub-id pub-id-type="doi">10.1021/jm5005978</pub-id><pub-id pub-id-type="pmid">24871036</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Makarov</surname><given-names>V</given-names></name><name><surname>Neres</surname><given-names>J</given-names></name><name><surname>Hartkoorn</surname><given-names>RC</given-names></name><etal/></person-group><article-title>The 8-pyrrole-benzothiazinones are noncovalent inhibitors of DprE1 from <italic>Mycobacterium tuberculosis</italic></article-title><source>Antimicrob Agents Chemother</source><year>2015</year><volume>59</volume><issue>8</issue><fpage>4446</fpage><lpage>4452</lpage><pub-id pub-id-type="doi">10.1128/AAC.00778-15</pub-id><pub-id pub-id-type="pmid">25987616</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neres</surname><given-names>J</given-names></name><name><surname>Hartkoorn</surname><given-names>RC</given-names></name><name><surname>Chiarelli</surname><given-names>LR</given-names></name><etal/></person-group><article-title>2-Carboxyquinoxalines kill <italic>Mycobacterium tuberculosis</italic> through noncovalent inhibition of DprE1</article-title><source>ACS Chem Biol</source><year>2014</year><volume>10</volume><issue>3</issue><fpage>705</fpage><lpage>714</lpage><pub-id pub-id-type="doi">10.1021/cb5007163</pub-id><pub-id pub-id-type="pmid">25427196</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tiwari</surname><given-names>R</given-names></name><name><surname>Miller</surname><given-names>PA</given-names></name><name><surname>Chiarelli</surname><given-names>LR</given-names></name><etal/></person-group><article-title>Design, syntheses, and anti-TB activity of 1,3-benzothiazinone azide and click chemistry products inspired by BTZ043</article-title><source>ACS Med Chem Lett</source><year>2016</year><volume>7</volume><issue>3</issue><fpage>266</fpage><lpage>270</lpage><pub-id pub-id-type="doi">10.1021/acsmedchemlett.5b00424</pub-id><pub-id pub-id-type="pmid">26985313</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Magnet</surname><given-names>S</given-names></name><name><surname>Hartkoorn</surname><given-names>RC</given-names></name><name><surname>Sz&#x000e9;kely</surname><given-names>R</given-names></name><etal/></person-group><article-title>Leads for antitubercular compounds from kinase inhibitor library screens</article-title><source>Tuberculosis</source><year>2010</year><volume>90</volume><issue>6</issue><fpage>354</fpage><lpage>360</lpage><pub-id pub-id-type="doi">10.1016/j.tube.2010.09.001</pub-id><pub-id pub-id-type="pmid">20934382</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shaikh</surname><given-names>MH</given-names></name><name><surname>Subhedar</surname><given-names>DD</given-names></name><name><surname>Arkile</surname><given-names>M</given-names></name><etal/></person-group><article-title>Synthesis and bioactivity of novel triazole incorporated benzothiazinone derivatives as antitubercular and antioxidant agent</article-title><source>Bioorg Med Chem Lett</source><year>2016</year><volume>26</volume><issue>2</issue><fpage>561</fpage><lpage>569</lpage><pub-id pub-id-type="doi">10.1016/j.bmcl.2015.11.071</pub-id><pub-id pub-id-type="pmid">26642768</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manina</surname><given-names>G</given-names></name><name><surname>Bellinzoni</surname><given-names>M</given-names></name><name><surname>Pasca</surname><given-names>MR</given-names></name><etal/></person-group><article-title>Biological and structural characterization of the <italic>Mycobacterium smegmatis</italic> nitroreductase NfnB, and its role in benzothiazinone resistance</article-title><source>Mol Microbiol</source><year>2010</year><volume>77</volume><issue>5</issue><fpage>1172</fpage><lpage>1185</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2958.2010.07277.x</pub-id><pub-id pub-id-type="pmid">20624223</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ribeiro</surname><given-names>ALDJL</given-names></name><name><surname>Degiacomi</surname><given-names>G</given-names></name><name><surname>Ewann</surname><given-names>F</given-names></name><etal/></person-group><article-title>Analogous mechanisms of resistance to benzothiazinones and dinitrobenzamides in <italic>Mycobacterium smegmatis</italic></article-title><source>PloS ONE</source><year>2011</year><volume>6</volume><issue>11</issue><fpage>e26675</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0026675</pub-id><pub-id pub-id-type="pmid">22069462</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pasca</surname><given-names>MR</given-names></name><name><surname>Degiacomi</surname><given-names>G</given-names></name><name><surname>Ribeiro</surname><given-names>ALdJL</given-names></name><etal/></person-group><article-title>Clinical isolates of <italic>Mycobacterium tuberculosis</italic> in four European hospitals are uniformly susceptible to benzothiazinones</article-title><source>Antimicrob Agents Chemother</source><year>2010</year><volume>54</volume><issue>4</issue><fpage>1616</fpage><lpage>1618</lpage><pub-id pub-id-type="doi">10.1128/AAC.01676-09</pub-id><pub-id pub-id-type="pmid">20086151</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Obreg&#x000f3;n-Henao</surname><given-names>A</given-names></name><name><surname>Wallach</surname><given-names>JB</given-names></name><etal/></person-group><article-title>Therapeutic potential of the <italic>Mycobacterium tuberculosis</italic> mycolic acid transporter, MmpL3</article-title><source>Antimicrob Agents Chemother</source><year>2016</year><volume>60</volume><issue>9</issue><fpage>5198</fpage><lpage>5207</lpage><pub-id pub-id-type="doi">10.1128/AAC.00826-16</pub-id><pub-id pub-id-type="pmid">27297488</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laughon</surname><given-names>BE</given-names></name><name><surname>Nacy</surname><given-names>CA</given-names></name></person-group><article-title>Tuberculosis&#x02014;drugs in the development pipeline</article-title><source>Nat Revi Dis Primers</source><year>2016</year></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sevilla</surname><given-names>IA</given-names></name><name><surname>Molina</surname><given-names>E</given-names></name><name><surname>Tello</surname><given-names>M</given-names></name><etal/></person-group><article-title>Detection of mycobacteria by culture and DNA-based methods in animal-derived food products purchased at Spanish supermarkets</article-title><source>Front Microbiol</source><year>2017</year><volume>8</volume><fpage>1030</fpage><pub-id pub-id-type="doi">10.3389/fmicb.2017.01030</pub-id><pub-id pub-id-type="pmid">28649235</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>DJ</given-names></name><name><surname>Adamopoulos</surname><given-names>IE</given-names></name></person-group><article-title>Loss of WDFY3 ameliorates severity of serum transfer-induced arthritis independently of autophagy</article-title><source>Cell Immunol</source><year>2017</year><volume>316</volume><fpage>61</fpage><lpage>69</lpage><pub-id pub-id-type="doi">10.1016/j.cellimm.2017.04.001</pub-id><pub-id pub-id-type="pmid">28449847</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stewart</surname><given-names>GR</given-names></name><name><surname>Robertson</surname><given-names>BD</given-names></name><name><surname>Young</surname><given-names>DB</given-names></name></person-group><article-title>Tuberculosis: a problem with persistence</article-title><source>Nat Rev Microbiol</source><year>2003</year><volume>1</volume><issue>2</issue><fpage>97</fpage><lpage>105</lpage><pub-id pub-id-type="doi">10.1038/nrmicro749</pub-id><pub-id pub-id-type="pmid">15035039</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pethe</surname><given-names>K</given-names></name><name><surname>Sequeira</surname><given-names>PC</given-names></name><name><surname>Agarwalla</surname><given-names>S</given-names></name><etal/></person-group><article-title>A chemical genetic screen in <italic>Mycobacterium tuberculosis</italic> identifies carbon-source-dependent growth inhibitors devoid of in vivo efficacy</article-title><source>Nat Commun</source><year>2010</year><volume>1</volume><issue>5</issue><fpage>1</fpage><pub-id pub-id-type="doi">10.1038/ncomms1060</pub-id><pub-id pub-id-type="pmid">20975674</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maddry</surname><given-names>JA</given-names></name><name><surname>Ananthan</surname><given-names>S</given-names></name><name><surname>Goldman</surname><given-names>RC</given-names></name><etal/></person-group><article-title>Antituberculosis activity of the molecular libraries screening center network library</article-title><source>Tuberculosis</source><year>2009</year><volume>89</volume><issue>5</issue><fpage>354</fpage><lpage>363</lpage><pub-id pub-id-type="doi">10.1016/j.tube.2009.07.006</pub-id><pub-id pub-id-type="pmid">19783214</pub-id></element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zumla</surname><given-names>A</given-names></name><name><surname>Nahid</surname><given-names>P</given-names></name><name><surname>Cole</surname><given-names>ST</given-names></name></person-group><article-title>Advances in the development of new tuberculosis drugs and treatment regimens</article-title><source>Nat Rev Drug Discov</source><year>2013</year><volume>12</volume><issue>5</issue><fpage>388</fpage><lpage>404</lpage><pub-id pub-id-type="doi">10.1038/nrd4001</pub-id><pub-id pub-id-type="pmid">23629506</pub-id></element-citation></ref><ref id="CR53"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lechartier</surname><given-names>B</given-names></name><name><surname>Rybniker</surname><given-names>J</given-names></name><name><surname>Zumla</surname><given-names>A</given-names></name><etal/></person-group><article-title>Tuberculosis drug discovery in the post-post-genomic era</article-title><source>EMBO Mol Med</source><year>2014</year></element-citation></ref><ref id="CR54"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kale</surname><given-names>RR</given-names></name><name><surname>Kale</surname><given-names>MG</given-names></name><name><surname>Waterson</surname><given-names>D</given-names></name><etal/></person-group><article-title>Thiazolopyridone ureas as DNA gyrase B inhibitors: optimization of antitubercular activity and efficacy</article-title><source>Bioorg Med Chem Lett</source><year>2014</year><volume>24</volume><issue>3</issue><fpage>870</fpage><lpage>879</lpage><pub-id pub-id-type="doi">10.1016/j.bmcl.2013.12.080</pub-id><pub-id pub-id-type="pmid">24405701</pub-id></element-citation></ref><ref id="CR55"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cooper</surname><given-names>CB</given-names></name></person-group><article-title>Development of <italic>Mycobacterium tuberculosis</italic> whole cell screening hits as potential antituberculosis agents: miniperspectives series on phenotypic screening for antiinfective targets</article-title><source>J Med Chem</source><year>2013</year><volume>56</volume><issue>20</issue><fpage>7755</fpage><lpage>7760</lpage><pub-id pub-id-type="doi">10.1021/jm400381v</pub-id><pub-id pub-id-type="pmid">23927683</pub-id></element-citation></ref><ref id="CR56"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wagner</surname><given-names>K</given-names></name><name><surname>Oehlmann</surname><given-names>L</given-names></name></person-group><article-title>Benzothiazol-<italic>N</italic>-oxide, IV1) Synthese und Reaktivit&#x000e4;t von 2-Cyanbenzothiazol-<italic>N</italic>-Oxiden und 2-Benzothiazolcarbonitrilen</article-title><source>Eur J Inorg Chem</source><year>1976</year><volume>109</volume><issue>2</issue><fpage>611</fpage><lpage>618</lpage></element-citation></ref><ref id="CR57"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsumoto</surname><given-names>M</given-names></name><name><surname>Hashizume</surname><given-names>H</given-names></name><name><surname>Tomishige</surname><given-names>T</given-names></name><etal/></person-group><article-title>OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice</article-title><source>PLoS Med</source><year>2006</year><volume>3</volume><issue>11</issue><fpage>e466</fpage><pub-id pub-id-type="doi">10.1371/journal.pmed.0030466</pub-id><pub-id pub-id-type="pmid">17132069</pub-id></element-citation></ref><ref id="CR58"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tiwari</surname><given-names>R</given-names></name><name><surname>Moraski</surname><given-names>GC</given-names></name><name><surname>Krch&#x00148;&#x000e1;k</surname><given-names>V</given-names></name><etal/></person-group><article-title>Thiolates chemically induce redox activation of BTZ043 and related potent nitroaromatic anti-tuberculosis agents</article-title><source>J Am Chem Soc</source><year>2013</year><volume>135</volume><issue>9</issue><fpage>3539</fpage><lpage>3549</lpage><pub-id pub-id-type="doi">10.1021/ja311058q</pub-id><pub-id pub-id-type="pmid">23402278</pub-id></element-citation></ref><ref id="CR59"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Balasubramanian</surname><given-names>V</given-names></name><name><surname>Solapure</surname><given-names>S</given-names></name><name><surname>Iyer</surname><given-names>H</given-names></name><etal/></person-group><article-title>Bactericidal activity and mechanism of action of AZD5847, a novel oxazolidinone for treatment of tuberculosis</article-title><source>Antimicrob Agents Chemother</source><year>2014</year><volume>58</volume><issue>1</issue><fpage>495</fpage><lpage>502</lpage><pub-id pub-id-type="doi">10.1128/AAC.01903-13</pub-id><pub-id pub-id-type="pmid">24189255</pub-id></element-citation></ref><ref id="CR60"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Landge</surname><given-names>S</given-names></name><name><surname>Ramachandran</surname><given-names>V</given-names></name><name><surname>Kumar</surname><given-names>A</given-names></name><etal/></person-group><article-title>Nitroarenes as antitubercular agents: stereoelectronic modulation to mitigate mutagenicity</article-title><source>ChemMedChem</source><year>2016</year><volume>11</volume><issue>3</issue><fpage>331</fpage><lpage>339</lpage><pub-id pub-id-type="doi">10.1002/cmdc.201500462</pub-id><pub-id pub-id-type="pmid">26751718</pub-id></element-citation></ref><ref id="CR61"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berry</surname><given-names>MP</given-names></name><name><surname>Graham</surname><given-names>CM</given-names></name><name><surname>McNab</surname><given-names>FW</given-names></name><etal/></person-group><article-title>An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis</article-title><source>Nature</source><year>2010</year><volume>466</volume><issue>7309</issue><fpage>973</fpage><lpage>977</lpage><pub-id pub-id-type="doi">10.1038/nature09247</pub-id><pub-id pub-id-type="pmid">20725040</pub-id></element-citation></ref><ref id="CR62"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bobesh</surname><given-names>KA</given-names></name><name><surname>Renuka</surname><given-names>J</given-names></name><name><surname>Jeankumar</surname><given-names>VU</given-names></name><etal/></person-group><article-title>Extending the N-linked aminopiperidine class to the mycobacterial gyrase domain: pharmacophore mapping from known antibacterial leads</article-title><source>Eur J Med Chem</source><year>2014</year><volume>85</volume><fpage>593</fpage><lpage>604</lpage><pub-id pub-id-type="doi">10.1016/j.ejmech.2014.08.018</pub-id><pub-id pub-id-type="pmid">25127151</pub-id></element-citation></ref></